The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you
  • Read on to discover how you can exploit the future business opportunities emerging in this sector.
  • In this brand new 236-page report you will receive 180 tables and 121 figures– all unavailable elsewhere.
  • The 236-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.
  • By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
  • Global Rheumatoid Arthritis Market forecast from 2020-2030
  • Revenue forecasts for the Rheumatoid Arthritis Market by Drug Class from 2020-2030:
  • Biologics
  • Non-Biologics: NSAIDs, sDMARDs, Others
Revenue forecasts for the Rheumatoid Arthritis Market by Drugs from 2020-2030:
  • Humira
  • Enbrel
  • Remicade
  • Rituxan/MabThera
  • Simponi/Simponi Aria
  • Orencia
  • Actemra/Roactemra
  • Cimzia
  • Celebrex
  • Xeljanz
  • Arcoxia
  • Others

Revenue forecasts for the Rheumatoid Arthritis Market by Region from 2020-2029:
  • North America: U.S., Canada
  • Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe
  • Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
  • Latin America: Brazil, Mexico, Rest of Latin America
  • Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA
Profiles of these selected leading companies:
  • AbbVie
  • Amgen, Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer
  • Sanofi S.A.
  • UCB
Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market
The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report:
  • How is the Rheumatoid Arthritis drugs market evolving?
  • What is driving and restraining the Rheumatoid Arthritis drugs market?
  • What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018?
  • How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030?
  • Which individual therapies will prevail and how will these shifts be responded to?
  • What will be the main driver for the overall market from 2020 to 2030?
  • How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2020 and 2030?